New Long-Acting shot for schizophrenia enters early human testing
NCT ID NCT06674694
First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This early-stage study is testing a single injection of a long-acting form of the drug brexpiprazole in healthy volunteers and people with schizophrenia. The main goal is to check if the injection is safe and tolerable, and how the body processes the drug. The trial involves 56 participants and will monitor side effects, vital signs, and lab tests for up to 90 days after the injection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brexpiprazole long-acting injection
What this could lead to
If successful, this could lead to a longer-acting treatment option for schizophrenia, potentially reducing the need for daily pills.
What could go wrong
This is an early Phase 1 trial with only 56 participants, focused on safety and dosing. It is too small and early to know if the injection will effectively control schizophrenia symptoms or have significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anding Hospital Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact